Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Avanos (AVNS) Earnings And Revenues Beat Estimates In Q4

By Zacks Investment ResearchStock MarketsFeb 26, 2020 09:56PM ET
www.investing.com/analysis/avanos-avns-earnings-and-revenues-beat-estimates-in-q4-200511392
Avanos (AVNS) Earnings And Revenues Beat Estimates In Q4
By Zacks Investment Research   |  Feb 26, 2020 09:56PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

Avanos Medical, Inc. (NYSE:AVNS) reported adjusted earnings per share (EPS) of 34 cents in fourth-quarter 2019, which surpassed the Zacks Consensus Estimate of 32 cents. The bottom line rose by a penny year over year.

For 2019, EPS was $1.07, up 30.5% from the 2018 figure.

Revenues of this Zacks Rank #4 (Sell) company were $189.8 million which beat the Zacks Consensus Estimate by 6.7%. Also, the figure improved 11.7% on a year-over-year basis.

Full-year revenues totaled $697.6 million, up 6.9%.

Q4 Segmental Analysis

Chronic Care

Net revenues at this segment of $113.4 million rose 15.5% year over year.

Pain Management

The segment reported net revenues of $76.4 million. The metric improved 6.6% on a year-over-year basis.

Margin Analysis

Gross profit came in at $109.7 million, up 9.3% from the prior-year quarter figure. Adjusted gross margin was 60% of net revenues, down 40 bps year over year.

Research and development expenses totaled $8.4 million, down 20.8% year over year. Selling, general and administrative expenses amounted to $103.6 million, up 17.9%.

Adjusted operating profit in the fourth quarter was $26 million, up 30% driven by higher sales volumes. The company reported operating loss of $3.2 million in the quarter under review compared with the year-ago quarter’s operating loss of $8.3 million.

Financial Update

As of Dec 31, 2019, cash and cash equivalents totaled $205.3 million.

Net cash from operating activities for the three months ended Dec 31, 2019, amounted to ($2.9) million, narrower than ($7.4 million) in the prior-year quarter.

Guidance

Avanos expects 2020 revenue growth between 5% and 7% compared to 2019. The Zacks Consensus Estimate for the same is pegged at $737.6 million.

Adjusted EPS is expected between a penny and $1.20. The Zacks Consensus Estimate stands at $1.18.

The company expects lower foreign currency impact in 2020 in comparison to 2019.

Summing Up

Avanos exited the fourth quarter on a strong note. The company continues to gain from core segments — Chronic Care and Pain Management. The recent FDA approval for the new 80-Watt COOLIEF Radiofrequency System buoys optimism. Also, the company completed the Endoclear LLC buyout and also entered into an operating partnership with DHL Supply Chain to enhance Avanos’ network achieve greater productivity and maximize warehouse storage utilization.

However, the contraction in gross margin is worrisome. Moreover, being a pure-play MedTech company, it faces stiff competition from other industry players.

Earnings of Other MedTech Majors at a Glance

Some better-ranked companies, which reported solid results this earnings season, include Stryker Corporation (NYSE:SYK) , Accuray Incorporated (NASDAQ:ARAY) and IDEXX Laboratories, Inc. (NASDAQ:IDXX) . You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Stryker reported fourth-quarter 2019 adjusted EPS of $2.49, outpacing the Zacks Consensus Estimate by 1.2%. Revenues of $4.13 billion surpassed the consensus estimate by 0.7%. The company carries a Zacks Rank #2 (Buy).

Accuray reported second-quarter fiscal 2020 adjusted EPS of a penny against the Zacks Consensus Estimate of a loss of 7 cents. Net revenues of $98.8 million outpaced the consensus mark by 0.3%. The company sports a Zacks Rank #1.

IDEXX Laboratories reported fourth-quarter 2019 adjusted EPS of $1.04, which beat the Zacks Consensus Estimate of 91 cents by 14.3%. Revenues were $605.4 million, surpassing the Zacks Consensus Estimate by 0.9%. The company carries a Zacks Rank of 2.

Today's Best Stocks from Zacks

Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.

This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.

See their latest picks free >>



Stryker Corporation (SYK): Free Stock Analysis Report

Accuray Incorporated (ARAY): Free Stock Analysis Report

IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report

AVANOS MEDICAL, INC. (AVNS): Free Stock Analysis Report

Original post

Zacks Investment Research
Avanos (AVNS) Earnings And Revenues Beat Estimates In Q4
 

Related Articles

Avanos (AVNS) Earnings And Revenues Beat Estimates In Q4

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email